Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. develops gene-edited cell and gene therapies as a clinical-stage biotechnology company. Its recurring news centers on allogeneic CAR T immunotherapies in oncology, including off-the-shelf, gene-edited CAR T-cell product candidates, and on broader gene therapy research using its gene-editing platform and in-house manufacturing capabilities.
Company updates commonly cover clinical and partner-program developments for candidates such as lasme-cel, eti-cel and cema-cel; TALE-based and epigenetic editing research; financial results and business updates; collaborations and license arrangements; and monthly disclosures of share capital and voting rights for its Euronext Growth listing alongside its Nasdaq-listed ADS trading under CLLS.
Cellectis (Nasdaq: CLLS), a clinical-stage biopharmaceutical company, announced participation in several investor conferences to showcase its advancements in gene-edited CAR T-cell therapies. Notable events include presentations at the Citi Annual BioPharma Conference on September 9, 2020, and the Wells Fargo Healthcare Conference on September 10, 2020. Cellectis focuses on developing innovative treatments for various cancers using proprietary technologies like TALEN® and PulseAgile.
The company's goal is to provide life-saving UCART therapies for unmet cancer treatment needs.